Gene Therapy in Treating Women With Refractory or Relapsed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed, refractory or relapsed, ovarian epithelial adenocarcinoma, fallopian tube cancer, or extraovarian peritoneal cancer for which no curative therapy exists
• * Must have tissue available from tumor biopsy to grow tumor cells ex vivo
• * Must have failed standard therapy with both a platinum agent (cisplatin or carboplatin) and paclitaxel
• Site of disease must be less than 5 cm in greatest diameter
• Evaluable disease by CT scan, physical exam, or laparoscopy
• No significant peritoneal fibrosis either from disease or prior surgery
• * Surgical lysis of adhesions allowed
• PATIENT CHARACTERISTICS:
• Age:
• 18 and over
• Performance status:
• ECOG 0-2
• Life expectancy:
• Not specified
• Hematopoietic:
• WBC greater than 2,000/mm3
• Absolute neutrophil count at least 1,000/mm3
• Platelet count at least 50,000/mm3
• Hemoglobin at least 8.5 g/dL (without transfusion)
• Hepatic:
• Bilirubin no greater than 2.0 mg/dL
• SGOT or SGPT no greater than 4 times upper limit of normal (ULN)
• Alkaline phosphatase no greater than 4 times ULN
• Hepatitis B surface antigen test required prior to study if transaminases greater than 2.0 times ULN
• No hepatitis B surface antigen
• Amylase normal
• PT and PTT normal
• Renal:
• Creatinine no greater than 2.0 mg/dL OR
• Creatinine clearance at least 50 mL/min
• Cardiovascular:
• No cardiac dysfunction by history and exam
• No ischemic heart disease that may be considered anesthetic or operative risk
• Pulmonary:
• No lung disease that may be considered anesthetic or operative risk
• Other:
• HIV negative
• Not pregnant or nursing
• No acute viral, bacterial, or fungal infection requiring medication within 14 days prior to study
• No patient with greater than 2 L of ascites at the time of intraperitoneal infusion
• No underlying condition that would preclude compliance
• No allergies to study reagent
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• Not specified
• Chemotherapy:
• See Disease Characteristics
• No concurrent chemotherapy
• Endocrine therapy:
• Not specified
• Radiotherapy:
• Not specified
• Surgery:
• See Disease Characteristics
• Other:
• No concurrent high dose vitamin regimens